ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
호흡기용 생물학적 제제 시장 규모는 향후 몇 년 동안 연평균 16.7%의 성장률로 2029년까지 138억 4,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 천식 및 COPD 유병률 증가, 생물학적 치료법 채택 증가, R&D 지출 증가, 비침습적 약물전달 방식에 대한 수요 증가, 상환 정책 확대 등의 요인에 기인합니다. 이 기간의 주요 동향으로는 호흡기질환에 대한 단클론항체 도입, 생물학적 제제 및 약물전달 기술의 발전, 규제 당국의 승인, 주요 기업 간 전략적 제휴 및 인수합병, 신약 개발 및 개발에 인공지능의 통합 등이 있습니다.
대기 오염의 증가는 향후 몇 년 동안 호흡기용 생물학적 제제 시장의 성장을 촉진할 것으로 예상됩니다. 대기오염은 대기 중에 가스, 미립자 물질, 생물학적 분자와 같은 유해 물질이 존재하여 인간의 건강과 환경 모두에 악영향을 미칠 수 있는 것을 말합니다. 대기오염의 증가는 산업화와 도시화가 진행되면서 공장, 자동차, 건설 활동으로 인한 배출량이 증가한 것이 주요 원인입니다. 호흡기용 생물학적 제제는 공기 중 오염 물질에 노출된 사람의 염증을 억제하고 폐 기능을 향상시키는 표적 치료제를 제공함으로써 대기 오염으로 인한 건강 영향에 대처하는 데 도움이 될 수 있습니다. 예를 들어, 2025년 1월 미국 환경보호청(EPA)은 2023년에 6,600만 톤 이상의 오염물질이 대기 중으로 배출되었다고 보고했습니다. 또한 2022년 9월 유엔환경계획에 따르면 대기오염으로 인해 매년 700만 명이 조기 사망하고, 전 세계 인구의 99%가 오염된 공기를 마시고 있다고 합니다. 그 결과, 대기 오염 수준의 상승이 호흡기용 생물학적 제제 시장의 성장을 촉진하고 있습니다.
호흡기용 생물학적 제제 시장의 주요 기업들은 만성 호흡기질환에 대한 표적 면역 치료와 같은 혁신적인 생물학적 치료법 개발에 주력하고 있으며, 염증을 억제하고 폐 기능을 향상시키는 정밀한 치료법을 제공하고 있습니다. 이러한 만성 호흡기질환에 대한 표적 면역 치료는 신체의 면역 체계를 관리하여 부종을 억제하고 장기적인 폐 질환의 호흡 곤란을 완화하도록 설계되어 있습니다. 예를 들어, 프랑스에 본사를 둔 제약회사 사노피(Sanofi S.A.)는 2024년 9월 미국 식품의약국(FDA)이 호산구 표현형을 가진 잘 조절되지 않는 만성폐쇄성폐질환(COPD) 성인 환자의 추가 유지요법으로 듀픽센트(Dupixent, 듀피루맙)를 승인했다고 발표했습니다. 이번 승인은 중요한 이정표로, 듀픽센트는 미국에서 이 특수한 COPD 환자군에 대해 승인된 최초의 생물학적 제제입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 호흡기용 생물학적 제제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 호흡기용 생물학적 제제 시장 : 성장률 분석
세계의 호흡기용 생물학적 제제 시장 실적 : 규모와 성장, 2019-2024
세계의 호흡기용 생물학적 제제 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 호흡기용 생물학적 제제 전체 시장(TAM)
제6장 시장 세분화
세계의 호흡기용 생물학적 제제 시장 : 질환 적응증별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
천식
만성 부비동염
호산구과다증후군
세계의 호흡기용 생물학적 제제 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
정맥내
피하
세계의 호흡기용 생물학적 제제 시장 : 판매 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
전문 클리닉
소매 약국
통신 판매 약국
세계의 호흡기용 생물학적 제제 시장 천식 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
중증호산구성 천식
알레르기성 천식
비알레르기성 천식
세계의 호흡기용 생물학적 제제 시장 만성 부비동염 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
비용종을 수반하는 만성 부비동염
비용종 없는 만성 부비동염
세계의 호흡기용 생물학적 제제 시장 호산구과다증후군(HES) 하위 세분화(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
특발성 HES
림프구 변이형 HES
골수 증식성 HES
제7장 지역별·국가별 분석
세계의 호흡기용 생물학적 제제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 호흡기용 생물학적 제제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
호흡기용 생물학적 제제 시장 : 경쟁 구도
호흡기용 생물학적 제제 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Sanofi S.A.
AstraZeneca plc
Novartis AG
GlaxoSmithKline plc
Amgen Inc.
Viatris Inc.
Regeneron Pharmaceuticals Inc.
Boehringer Ingelheim International GmbH
Biogen Inc.
Vertex Pharmaceuticals Incorporated
Swedish Orphan Biovitrum AB
Glenmark Pharmaceuticals Ltd.
Zymeworks Inc.
Kiniksa Pharmaceuticals Ltd.
Pieris Pharmaceuticals Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
호흡기용 생물학적 제제 시장 2029 : 새로운 기회를 제공하는 국가
호흡기용 생물학적 제제 시장 2029 : 새로운 기회를 제공하는 부문
호흡기용 생물학적 제제 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Respiratory biologics are a class of targeted therapies derived from living organisms, used to treat chronic respiratory conditions. These biologics typically focus on specific molecules in the immune system, such as interleukins (IL-4, IL-5, IL-13) or immunoglobulin E (IgE), to reduce inflammation and enhance breathing. They are primarily prescribed to patients with severe, uncontrolled respiratory diseases that do not respond adequately to standard treatments such as inhaled corticosteroids and bronchodilators.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary conditions treated with respiratory biologics include asthma, chronic rhinosinusitis, and hypereosinophilic syndrome. Asthma is a chronic inflammatory disorder of the airways that leads to breathing problems, wheezing, and coughing due to airway narrowing and heightened sensitivity. These biologics are available in various forms, such as intravenous and subcutaneous injections, and are distributed through different channels, including hospitals, specialty clinics, retail pharmacies, and mail-order pharmacies.
The respiratory biologics market research report is one of a series of new reports from The Business Research Company that provides respiratory biologics market statistics, including the respiratory biologics industry global market size, regional shares, competitors with the respiratory biologics market share, detailed respiratory biologics market segments, market trends, and opportunities, and any further data you may need to thrive in the respiratory biologics industry. These respiratory biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The respiratory biologics market size has grown rapidly in recent years. It will grow from $6.38 billion in 2024 to $7.47 billion in 2025 at a compound annual growth rate (CAGR) of 17.0%. The growth observed in the historical period can be attributed to several factors, including the rising prevalence of respiratory diseases, the growing adoption of personalized medicine, increased global healthcare spending, heightened awareness and diagnosis rates of respiratory conditions, and an expanding elderly population with respiratory disorders.
The respiratory biologics market size is expected to see rapid growth in the next few years. It will grow to $13.84 billion in 2029 at a compound annual growth rate (CAGR) of 16.7%. The growth projected for the forecast period can be attributed to factors such as the rising prevalence of asthma and COPD, increasing adoption of biologic therapies, higher spending on R&D, growing demand for non-invasive drug delivery methods, and the expansion of reimbursement policies. Key trends during this period include the adoption of monoclonal antibodies for respiratory diseases, advancements in biologic drug formulations and delivery techniques, regulatory approvals, strategic collaborations and acquisitions among major players, and the integration of artificial intelligence in drug discovery and development.
The growing levels of air pollution are expected to drive the expansion of the respiratory biologics market in the coming years. Air pollution refers to the presence of harmful substances, such as gases, particulate matter, and biological molecules, in the atmosphere, which can negatively impact both human health and the environment. The rise in air pollution is largely due to increased industrialization and urbanization, resulting in higher emissions from factories, vehicles, and construction activities. Respiratory biologics help address the health effects of air pollution by offering targeted therapies that reduce inflammation and enhance lung function in individuals exposed to airborne pollutants. For example, in January 2025, the United States Environmental Protection Agency (EPA) reported that over 66 million tons of pollutants were released into the atmosphere in 2023. Additionally, according to the United Nations Environment Programme in September 2022, air pollution causes 7 million premature deaths each year, and 99% of the global population breathes polluted air. Consequently, the rising levels of air pollution are driving the growth of the respiratory biologics market.
Leading companies in the respiratory biologics market are focusing on developing innovative biologic therapies, such as targeted immune treatments for chronic respiratory diseases, to provide precise treatments that reduce inflammation and enhance lung function. These targeted immune therapies for chronic respiratory diseases are designed to manage the body's immune system to reduce swelling and alleviate breathing difficulties in long-term lung conditions. For example, in September 2024, Sanofi S.A., a pharmaceutical company based in France, announced that the US Food and Drug Administration (FDA) had approved Dupixent (dupilumab) as an add-on maintenance therapy for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) who have an eosinophilic phenotype. This approval was a significant milestone, making Dupixent the first biologic medication authorized in the US for this particular group of COPD patients.
In February 2024, GlaxoSmithKline plc, a UK-based pharmaceutical company, acquired Aiolos Bio for an undisclosed amount. With this acquisition, GSK aims to enhance its respiratory and immunology portfolio by gaining access to Aiolos Bio's innovative treatments for inflammatory and immune-mediated diseases. Aiolos Bio is a US-based company focused on developing biological therapies for respiratory and inflammatory conditions.
Major players in the respiratory biologics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Swedish Orphan Biovitrum AB, Glenmark Pharmaceuticals Ltd., Zymeworks Inc., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.
North America was the largest region in the respiratory biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory biologics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the respiratory biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The respiratory biologics market consists of sales of monoclonal antibodies (mAbs), interleukin inhibitors, and immunomodulators. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Respiratory Biologics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on respiratory biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for respiratory biologics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The respiratory biologics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Disease Indication: Asthma; Chronic Rhinosinasitis; Hypereosinophilic Syndrome
2) By Route Of Administration: Intravenous; Subcuteneous
3) By Sales Channel: Hospitals; Specialty Clinics; Retail Pharmacies; Mail Order Pharmacies
Subsegments::
1) By Asthma: Severe Eosinophilic Asthma; Allergic Asthma; Non-Allergic Asthma
2) By Type: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps; Chronic Rhinosinusitis without Nasal Polyps
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Respiratory Biologics Market Characteristics
3. Respiratory Biologics Market Trends And Strategies
4. Respiratory Biologics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Respiratory Biologics Growth Analysis And Strategic Analysis Framework
5.1. Global Respiratory Biologics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Respiratory Biologics Market Growth Rate Analysis
5.4. Global Respiratory Biologics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Respiratory Biologics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Respiratory Biologics Total Addressable Market (TAM)
6. Respiratory Biologics Market Segmentation
6.1. Global Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Asthma
Chronic Rhinosinasitis
Hypereosinophilic Syndrome
6.2. Global Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous
Subcuteneous
6.3. Global Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Retail Pharmacies
Mail Order Pharmacies
6.4. Global Respiratory Biologics Market, Sub-Segmentation Of Asthma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Severe Eosinophilic Asthma
Allergic Asthma
Non-Allergic Asthma
6.5. Global Respiratory Biologics Market, Sub-Segmentation Of Chronic Rhinosinusitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chronic Rhinosinusitis with Nasal Polyps
Chronic Rhinosinusitis without Nasal Polyps
6.6. Global Respiratory Biologics Market, Sub-Segmentation Of Hypereosinophilic Syndrome (HES), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Idiopathic HES
Lymphocytic Variant HES
Myeloproliferative HES
7. Respiratory Biologics Market Regional And Country Analysis
7.1. Global Respiratory Biologics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Respiratory Biologics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Respiratory Biologics Market
9.1. China Respiratory Biologics Market Overview
9.2. China Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Respiratory Biologics Market
10.1. India Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Respiratory Biologics Market
11.1. Japan Respiratory Biologics Market Overview
11.2. Japan Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Respiratory Biologics Market
12.1. Australia Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Respiratory Biologics Market
13.1. Indonesia Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Respiratory Biologics Market
14.1. South Korea Respiratory Biologics Market Overview
14.2. South Korea Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Respiratory Biologics Market
15.1. Western Europe Respiratory Biologics Market Overview
15.2. Western Europe Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Respiratory Biologics Market
16.1. UK Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Respiratory Biologics Market
17.1. Germany Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Respiratory Biologics Market
18.1. France Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Respiratory Biologics Market
19.1. Italy Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Respiratory Biologics Market
20.1. Spain Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Respiratory Biologics Market
21.1. Eastern Europe Respiratory Biologics Market Overview
21.2. Eastern Europe Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Respiratory Biologics Market
22.1. Russia Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Respiratory Biologics Market
23.1. North America Respiratory Biologics Market Overview
23.2. North America Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Respiratory Biologics Market
24.1. USA Respiratory Biologics Market Overview
24.2. USA Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Respiratory Biologics Market
26.1. South America Respiratory Biologics Market Overview
26.2. South America Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Respiratory Biologics Market
27.1. Brazil Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Respiratory Biologics Market
28.1. Middle East Respiratory Biologics Market Overview
28.2. Middle East Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Respiratory Biologics Market
29.1. Africa Respiratory Biologics Market Overview
29.2. Africa Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Respiratory Biologics Market Competitive Landscape And Company Profiles
